4//SEC Filing
ODell William F 4
Accession 0001209191-12-058874
CIK 0000879993other
Filed
Dec 19, 7:00 PM ET
Accepted
Dec 20, 5:28 PM ET
Size
18.6 KB
Accession
0001209191-12-058874
Insider Transaction Report
Form 4
ODell William F
Exec. VP Sales and Marketing
Transactions
- Disposition from Tender
Common Stock
2012-12-20$8.00/sh−53,560$428,480→ 0 total - Disposition to Issuer
Non-qualified Stock Options
2012-12-20−25,000→ 0 totalExercise: $3.37From: 2008-03-20Exp: 2014-03-20→ Common Stock (25,000 underlying) - Disposition to Issuer
Non-qualified Stock Options
2012-12-20−75,100→ 0 totalExercise: $1.22From: 2010-03-13Exp: 2016-03-13→ Common Stock (75,100 underlying) - Disposition from Tender
Common Stock
2012-12-20$8.00/sh−219,150$1,753,200→ 0 total - Disposition to Issuer
Non-qualified Stock Options
2012-12-20−19,500→ 0 totalExercise: $2.20From: 2009-05-09Exp: 2015-05-09→ Common Stock (19,500 underlying) - Disposition to Issuer
Non-qualified Stock Options
2012-12-20−50,000→ 0 totalExercise: $6.90From: 2007-04-17Exp: 2016-04-16→ Common Stock (50,000 underlying) - Disposition to Issuer
Non-qualified Stock Options
2012-12-20−85,000→ 0 totalExercise: $1.65From: 2011-03-05Exp: 2017-03-04→ Common Stock (85,000 underlying)
Footnotes (2)
- [F1]These shares are restricted shares. Pursuant to the Agreement and Plan of Merger, dated as of November 8, 2012, by and among, Sun Pharmaceutical Industries Limited as assigned to Caraco Pharmaceutical Laboratories, Ltd., Caraco Acquisition Corporation and DUSA Pharmaceuticals, Inc. (the "Merger Agreement"), immediately prior to the date and time the merger becomes effective, each restricted share that is then outstanding and unvested shall immediately vest and become nonforfeitable, all restrictions and conditions applicable thereto shall lapse, and each restricted share shall be treated in the same manner as each other share of Company Common Stock in the merger and is cancelled in exchange for the right to receive cash payment for each such restricted share of $8.00.
- [F2]Pursuant to the Merger Agreement, each in-the-money stock option, whether vested or unvested, that is outstanding immediately prior to the Acceptance Time shall become fully vested immediately prior to the Acceptance Time, and be cancelled as of the Acceptance Time in exchange for the right to receive at such time a lump sum cash payment of an amount equal to (i) the Offer Price less (ii) the exercise price payable in respect of each such share of Company Common Stock issuable under such option, net of applicable taxes, if any, with respect to such option.
Documents
Issuer
DUSA PHARMACEUTICALS INC
CIK 0000879993
Entity typeother
Related Parties
1- filerCIK 0001357876
Filing Metadata
- Form type
- 4
- Filed
- Dec 19, 7:00 PM ET
- Accepted
- Dec 20, 5:28 PM ET
- Size
- 18.6 KB